ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data

Coverage, in order

1. 16d ago
   
   BioPharma Dive indie

   ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data

   At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.